IL-17F, Human
| $190.00 | |
| Z02713-25 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $190.00 | |
| Z02713-25 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | |
| Protein Construction |
Expressed with an N-terminal Met.
|
|
| Purity |
> 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC |
|
| Endotoxin Level | < 1 EU/μg of protein by LAL method | |
| Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by inducing IL-6 secretion of murine NIH/3T3 cells is less than 20.0 ng/ml, corresponding to a specific activity of > 5.0 × 104 IU/mg. | |
| Expression System | E. coli | |
| Theoretical Molecular Weight | 30.1 kDa | |
| Formulation | Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4. | |
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in 6 mM HCl up to 100 μg/mL. | |
| Storage & Stability | Upon receiving, this product remains stable for 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for 1 week at 4°C or for 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background | Human IL-17F is synthesized as a 153 aa precursor with a 20 aa signal sequence and a 133 aa mature region. Like IL-17A, IL-17F contains one potential site for N-linked glycosylation. IL-17A and IL-17F share 50% aa sequence identity. IL17-F homodimer is produced by an activated subset of CD4+ T cells, termed Th17. IL17-F has been shown to stimulate proliferation and activation of T-cells and PBMCs. IL-17F also regulates cartilage matrix turnover and inhibits angiogenesis. |
| Synonyms | Interleukin-17F; IL17F |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.